Skip to main content

Security report for angelinipharma.co.uk

Angelini Pharma UK & Ireland · Healthcare · United Kingdom

Low risk. 2 critical or high findings in GDPR outside view and SSL/TLS.

Security score

77/100

Risk levelLow

0–100, higher is better. How it is calculated

Angelini Pharma UK & Ireland operates as a pharmaceutical company focusing on brain health and epilepsy-related health solutions. It is part of the larger Angelini Industries group, with a professional and consistent online presence targeting healthcare professionals and patients. The website provides comprehensive information about the company, its products, and corporate responsibility initiatives. Technically, the site uses modern JavaScript libraries and analytics tools, ensuring a good user experience with mobile optimization and clear navigation. Security posture is solid with HTTPS and anonymized analytics, though some security headers and explicit security policies are missing. WHOIS data is unavailable due to domain naming rules errors, which slightly impacts trust but does not detract from the overall legitimacy given the professional content and clear company information.

Scanned

NIS2 and GDPR posture

GDPR outside view
68/ 100 · Medium
Checks completed
7of 7

NIS2 Art. 21(2)

  1. (a) Risk analysis and security policies: Not visible from outside
  2. (b) Incident handling: One indicator
  3. (c) Business continuity, backups and crisis management: Not visible from outside
  4. (d) Supply chain security: Not visible from outside
  5. (e) Secure acquisition, development and maintenance, including vulnerability handling: Partly checked
  6. (f) Assessing the effectiveness of security measures: Not visible from outside
  7. (g) Cyber hygiene and security training: Not visible from outside
  8. (h) Cryptography and encryption: Partly checked
  9. (i) HR security, access control and asset management: One indicator
  10. (j) Multi-factor authentication and secured communications: Not visible from outside

This scan rated NIS2 with an earlier keyword method that is no longer shown; rescan for the per-article view. Risk management, continuity, supply chain, training, MFA, management oversight (Art. 20) and incident reporting (Art. 23) need internal evidence, and Guard cannot tell whether NIS2 applies to this organisation.

GDPR is indicative only, based on publicly visible signals: Articles 7, 12, 13 and 32 of Regulation (EU) 2016/679 and Article 5(3) of the ePrivacy Directive. Not a certification or legal assessment.

Priority findings

2 findings rated critical or high. Fix these first.

  1. GDPR outside view

    These are the privacy signals visitors and data protection authorities look for under GDPR.

    • High

      No Cookie Consent Banner found

      GDPR requires explicit consent for non-essential cookies

      What to do: Implement a cookie consent banner that appears on first visit

  2. SSL/TLS

    TLS encrypts the connection and proves the site is really yours. Weak or expiring certificates trigger browser warnings and put traffic at risk.

    • High

      Weak Protocols Supported

      Server supports weak protocols: TLSv1.1

      What to do: Disable TLS 1.0, TLS 1.1, and all SSL versions

      • CWE-327
      • OWASP A04:2025
      • ASVS V12.1.1

Need hands-on remediation? Email guard@offseq.com

Keep watching angelinipharma.co.uk

This scan found 19 issues across 6 checks. Monitoring re-runs those checks daily, emails you when something material changes and records each fix, so you can show progress.

Daily monitoring

Recommended

€25per month

  • TLS certificates and expiry
  • DNS records
  • SPF, DKIM and DMARC
  • Security headers
  • GDPR and NIS2 posture
  • Exposed services
  • Third-party trackers
  • Security score drift

Email alerts on material changes and an exportable JSON history of every change.

Billed monthly to your card. Cancel anytime. The full timeline opens with your unlock code.

Full report

€39.90one-time

  • The complete analysis as a PDF you can cite
  • Email delivery with an unlock code
  • Lifetime access to this report

Prices incl. 21% VAT. Secure checkout by Mollie; sold by SEQ SIA, Latvia.

Results by check

Each check with its score, findings and the evidence it collected.

How this score is calculated

The security score runs 0–100, higher is better. It is the plain average of the security checks that completed in this scan, each counted equally. A check that could not run is left out: it counts neither as a pass nor as a fail.

Counted in this score

SSL/TLS
72
Security headers
90
Email security
70
DNS health
60
Network security
100
GDPR outside view
68
Average
77

Not counted

  • NIS2 outside view: Re-weights evidence from the TLS, email, DNS, network and hygiene checks, so counting it would count that evidence twice. Shown on its own.
  • OffSeq Observations: An AI reading of the site, useful context but not reproducible evidence. Shown on its own.

Findings that cap the score at 49

Each of these is serious on its own, so while any is present the site cannot rate better than high risk, however good the other checks are.

  • The certificate is not trusted by browsers
  • The website is not served over HTTPS
  • A database, remote desktop, file-sharing or Telnet service is reachable from the internet
  • The page loads a script from a compromised source
  • The domain registration has expired
  • SPF authorises every server to send mail as the domain

Partial scans

When the site blocks Guard or most checks cannot run, the score covers only the checks that ran (usually DNS and email), is capped at 75 and is shown as partial, without a risk level.

Risk levels

  • Critical0–25
  • High26–49
  • Medium50–75
  • Low76–100

Technical appendix

Business context, site observations and technical notes gathered during the scan, and the standards behind each reference.

Business context

Business profile

Angelini Pharma UK & Ireland holds a medium-sized position in the healthcare sector, specializing in pharmaceuticals with a focus on brain health and epilepsy. The company benefits from being part of the Angelini group, which provides a broad geographic footprint and product portfolio. The business model centers on pharmaceutical product development and distribution, targeting healthcare providers and patients. The website reflects a mature digital presence with clear branding, trust indicators such as certifications, and links to multiple country-specific subsidiaries. The company maintains transparency through privacy and cookie policies and demonstrates compliance with GDPR. The lack of phone contact may indicate a preference for email communication or regulatory considerations in pharma.

Security posture

The website demonstrates a good security posture with enforced HTTPS and use of privacy-conscious analytics (Piwik PRO with anonymization). However, the absence of key security headers such as Content-Security-Policy and Strict-Transport-Security reduces the overall security score. No vulnerabilities or exposed sensitive data were detected in the HTML content. The site lacks explicit security policy or incident response pages, which could improve transparency and readiness. No security.txt file or vulnerability disclosure mechanism is present, which is recommended for organizations handling sensitive health-related information. Overall, the security maturity is moderate with room for improvement in headers and policy disclosures.

Recommendations

  1. Implement comprehensive security headers including Content-Security-Policy, X-Content-Type-Options, X-Frame-Options, and Strict-Transport-Security to enhance protection against common web attacks.
  2. Publish explicit security policy and incident response information on the website to improve transparency and preparedness.
  3. Add a security.txt file to facilitate responsible vulnerability disclosure and improve trust with security researchers.
  4. Enhance accessibility features to meet higher compliance standards and improve user experience for all visitors.
  5. Regularly audit and update third-party scripts and analytics tools to mitigate risks from vulnerable libraries.

Contact details published on the site

Addresses
Legal name
Angelini Pharma UK & Ireland
VAT number
GB387249551
Registration number
13473950
Site observations

Automated reading of the public site. Ratings are indicative.

Business

Company
Angelini Pharma UK & Ireland
Description
Angelini Pharma UK & Ireland is committed to identifying health solutions with a prevalent focus on epilepsy. It is part of Angelini Industries and operates in the pharmaceutical sector offering products mainly in brain health and related therapeutic areas.
Key services
Pharmaceutical product development, Distribution of medicines, Health solutions focused on epilepsy and brain health
Content quality
good
Branding
consistent

Technology

Stack
jQuery 3.7.1, jQuery Validation, Slick Carousel, Magnific Popup, Piwik PRO analytics, Flip.js, Google Fonts (custom domain), Spreaker Widgets
Performance
moderate
Mobile
good
Accessibility
basic
SEO
good

Security

Observed score
80/100
Good practices seen
  • HTTPS enforced
  • No exposed sensitive data in HTML
  • Use of analytics with anonymization options

Analytics and tracking

Services
Piwik PRO
Tracking level
moderate
Privacy practices
good

Advertising

Tracking pixels
Piwik PRO
Marketing tools
Piwik PRO analytics
Transparency
basic

Site quality

Design
good
User experience
good
Content relevance
good
Navigation
good
Professionalism
good
Trustworthiness
high

Key observations

  1. Website is fully accessible with no blocking or WAF challenges.
  2. Content is focused on pharmaceutical products and corporate responsibility.
  3. Clear navigation with multiple sections including Who We Are, Core Areas, Products, Responsibility, Media, and Contact.
  4. Use of modern JavaScript libraries and analytics tools.
  5. Presence of privacy and cookie policies with consent mechanisms.
  6. WHOIS data is unavailable due to domain naming rules error, which is unusual but does not appear to impact website legitimacy.
  7. No security.txt or explicit security policy pages found.
  8. No contact phone numbers explicitly labeled found; only email and physical address provided.
  9. No forms collecting personal data detected on the homepage or main navigation.
Technical notes

Notes

The website uses a modern and well-maintained technology stack including jQuery 3.7.1, Slick Carousel, Magnific Popup, and Piwik PRO analytics. Fonts are served from a custom Angelini domain, indicating control over assets. The site is mobile-optimized with responsive design and good navigation clarity. Performance is moderate, likely due to multiple external scripts and media assets. No CMS is explicitly detected, suggesting a custom or proprietary platform. Hosting provider details are not evident from the HTML content. The site uses asynchronous and deferred loading for scripts, improving load times. SEO is supported by proper meta tags and Open Graph data. Overall, the technical infrastructure is solid with opportunities for performance tuning and enhanced accessibility.
Standards and sources

Reference chips under each finding point to the standard, regulation or specification the finding relates to. They are taken from the official datasets below and mapped conservatively: a finding with no defensible link shows none. NIS2 and GDPR references mark where a finding is relevant evidence, not a compliance verdict. Implementing Regulation (EU) 2024/2690 binds digital infrastructure and digital service providers; for other entities it is the most detailed public reading of the Article 21 measures. WCAG, EN 301 549, European Accessibility Act and Web Accessibility Directive references name the requirement an automated accessibility rule relates to; they are not a conformance verdict.

Retrieved 2026-10-25

Reviews of this site

Share your experience with angelinipharma.co.uk. Every review is verified by email and published after moderation.

Overall rating
Select a rating
4000 characters remaining

We’ll email you to confirm your review and keep your details private.

Community rating

No published reviews yet. Be the first to review angelinipharma.co.uk.

Feedback on this report

Rate this report, add an optional comment, and tell us if you want a security specialist to follow up.

Overall report quality
Select a rating
2000 characters remaining

We only use your feedback to improve Guard reports. Contact details are never shared.